Calamos Advisors
XERS icon

Calamos Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Calamos Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-99,117
Closed -$778K – 1281
2025
Q4 		$778K Sell
99,117
-37,980
-28% -$299K ﹤0.01% 719
2025
Q3 		$1.12M Buy
+137,097
New +$911K ﹤0.01% 695

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Calamos Advisors's XERS Position: Q1 2026 in Review

Calamos Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 99,117 shares — an estimated $778K sold.

Calamos Advisors first reported a position in XERS in Q3 2025 and held it in 2 quarters. The position peaked at $1.12M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Calamos Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
  • Calamos Advisors sold 99,117 Xeris Biopharma Holdings shares in Q1 2026, an estimated $778K.
  • Calamos Advisors first reported a position in Xeris Biopharma Holdings in Q3 2025 and held it in 2 quarters.
  • Calamos Advisors's Xeris Biopharma Holdings position peaked at $1.12M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.